RRRusham Zahra Rana

Rusham Zahra Rana

*This is an algorithmically generated author record based on publicly available information.

Rusham Zahra Rana has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Core outcome sets for trials of interventions to prevent and to treat multimorbidity in adults in low and middle-income countries: the COSMOS study

    by Aishwarya Lakshmi Vidyasagaran, Rubab Ayesha, Jan R Boehnke, Jamie Kirkham, Louise Rose, John R Hurst, Juan Jaime Miranda, Rusham Zahra Rana, Rajesh Vedanthan, Mehreen Riaz Faisal, et al.

    Introduction The burden of multimorbidity is recognised increasingly in low- and middle-income countries (LMICs), creating a strong emphasis on the need for effective evidence-based interventions. Core outcome sets (COS) appropriate for the study of multimorbidity in LMICs do not presently exist. These are required to standardise reporting and contribute to a consistent and cohesive evidence-base to inform policy and practice. We describe the development of two COS for intervention trials aimed at preventing and treating multimorbidity in adults in LMICs. Methods To generate a comprehensive list of relevant prevention and treatment outcomes, we conducted a systematic review and qualitative interviews with people with multimorbidity and their caregivers living in LMICs. We then used a modified two-round Delphi process to identify outcomes most important to four stakeholder groups (people with multimorbidity/caregivers, multimorbidity researchers, healthcare professionals and policymakers) with representation from 33 countries. Consensus meetings were used to reach agreement on the two final COS. Registration: https://www.comet-initiative.org/Studies/Details/1580. Results The systematic review and qualitative interviews identified 24 outcomes for prevention and 49 for treatment of multimorbidity. An additional 12 prevention and 6 treatment outcomes were added from Delphi round 1. Delphi round 2 surveys were completed by 95 of 132 round 1 participants (72.0%) for prevention and 95 of 133 (71.4%) participants for treatment outcomes. Consensus meetings agreed four outcomes for the prevention COS: (1) adverse events, (2) development of new comorbidity, (3) health risk behaviour and (4) quality of life; and four for the treatment COS: (1) adherence to treatment, (2) adverse events, (3) out-of-pocket expenditure and (4) quality of life. Conclusion Following established guidelines, we developed two COS for trials of interventions for multimorbidity prevention and treatment, specific to adults in LMIC contexts. We recommend their inclusion in future trials to meaningfully advance the field of multimorbidity research in LMICs. PROSPERO registration number CRD42020197293.


  • Open Access

    Development of a core outcome set for multimorbidity trials in low- and middle-income countries (COSMOS): Study Protocol

    by Jan R. Boehnke, Rusham Zahra Rana, Jamie J. Kirkham, Louise Rose, Gina Agarwal, Corrardo Barbui, Alyssa Chase, Rachel Churchill, Oscar Flores-Flores, John R. Hurst, et al.

    Introduction ‘Multimorbidity’ describes the presence of two or more long-term conditions, which can include communicable and non-communicable diseases, and mental disorders. The rising global burden from multimorbidity is well-documented, but trial evidence for effective interventions in low- and middle-income countries (LMICs) is limited. Selection of appropriate outcomes is fundamental to trial design to ensure cross-study comparability, but there is currently no agreement on a core outcome set (COS) to include in trials investigating multimorbidity specifically in LMIC. Our aim is to develop international consensus on two COS for trials of interventions to prevent and treat multimorbidity in LMIC settings. Methods and Analysis Following methods recommended by the Core Outcome Measures in Effectiveness Trials (COMET initiative), the development of these two COS will occur in three stages: (1) generation of a long list of potential outcomes for inclusion; (2) two-round online Delphi surveys; and (3) consensus meetings. First, to generate an initial list of outcomes, we will conduct a systematic review of multimorbidity intervention and prevention trials and interviews with people living with multimorbidity and their caregivers in LMICs. Outcomes will be classified using an outcome taxonomy. Two-round Delphi surveys will be used to elicit importance scores for these outcomes from people living with multimorbidity, caregivers, healthcare professionals, policy makers, and researchers in LMICs. Finally, consensus meetings will be held to discuss the Delphi survey results and agree outcomes for inclusion in the two COS. Ethics and dissemination The study has been approved by the Research Governance Committee of the Department of Health Sciences, University of York, UK [HSRGC/2020/409/D:COSMOS]. Each participating country/research group will obtain local ethics board approval. Informed consent will be obtained from all participants. We will disseminate findings through peer-reviewed open access publications, and presentations at global conferences selected to reach a wide range of LMIC stakeholders. Trial registration PROSPERO ID CRD42020197293 COMET https://www.comet-initiative.org/Studies/Details/1580 Strengths and limitations of this study The development process follows guidelines and best practice recommendations for developing core outcome sets and integrates four sources of information. Interviews with people living with multimorbidity and caregivers are conducted in several LMICs (in South Asia, Africa and Latin America), by local teams, and in local languages to identify outcomes relevant to them. The Delphi survey and consensus meetings are conducted in English which limits the breadth of participation in these stages of the process. Despite involvement of a wide range of LMIC stakeholders in the process, there may be some limitations to the generalisability of the final core outcome sets due to the heterogeneity of target conditions and the diversity of countries, cultures and experiences.

  • Open Access

    Behavioural activation therapies for depression in adults with non-communicable diseases

    by Eleonora Uphoff, Malini Pires, Corrado Barbui, Deepa Barua, Rachel Churchill, David Ekers, Edward Fottrell, Papiya Mazumdar, Marianna Purgato, Rusham Rana, et al.

    This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to examine the effects of behavioural activation compared to any control group for the treatment of depression in adults with non‐communicable diseases (NCDs). The secondary objectives is to examine the effects of behavioural activation compared to each control group separately (no treatment, waiting list, other psychological therapy, pharmacological treatment, or any other type of treatment as usual) for the treatment of depression in adults with NCDs.